Ironwood Pharmaceuticals, Inc. (IRWD)

From the record

Ironwood Pharmaceuticals, Inc.'s filings since 2017 show 4 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2025-06-03); an auditor change (8-K item 4.01, the latest 2025-07-10); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2025-03-03) (its current reports).

From the record

Ironwood Pharmaceuticals, Inc.'s 10 filed years say what it did: revenue went from $274 million in fiscal 2016 to $296 million in fiscal 2025, up 0.9% a year; it rose in 5 of 9 years; the deepest fall was 33% from fiscal 2023 to fiscal 2025; net income was positive in 6 of 9 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Ironwood Pharmaceuticals, Inc.'s diluted share count shrank about 4.4% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 18 sales (3 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Ironwood Pharmaceuticals, Inc.'s shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 166 cents per dollar of assets, and net share issuance: its share count grew 1.8% over the year (the filed statements).

From the record

Ironwood Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $296 million in fiscal 2025 ranks in the top 23% by size; a net margin of 8.1% ranks in the top 18%; revenue growth of -10.3% a year over the last 3 filed years ranks in the bottom 26% (its annual reports).

From the record

Ironwood Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Mccourt, Thomas A (Chief Executive Officer, as filed), filing under that title since 2021-03-30, 5.6 years (top 44% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 6.3 years (top 36%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (bottom 29%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Ironwood Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $215 million against no long-term debt tagged leaves 54.3% of its assets as net cash, top 31% of its family; cash from operations less capital spending is 42.9% of revenue (top 4%); research spending of 32.1% of revenue (bottom 35%) (its annual report).

From the record

Ironwood Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -10.3% a year over the last three filed years against 0.9% over all 10, slowing (bottom 32% of its family); the newest year grew -15.7% (bottom 28%); research spending grew 29% a year (top 15%); capital spending grew -37% a year (bottom 32%) (its annual reports). Ironwood Pharmaceuticals, Inc. reported 2 product lines in fiscal 2025: Collaborative Arrangements at $296 million (100%), Collaborative Arrangement Other Agreements at $87 thousand (0%); 0 of 2 grew against the year before (its annual report).

From the record

Ironwood Pharmaceuticals, Inc.'s newest year against its own record: revenue of $296 million in fiscal 2025 came in 8.9% below the $325 million its prior three years' pace pointed to (bottom 41% of its family); net income of $24 million against a prior three-year average of $275 million (top 14%); a net margin of 8.1% against -61.2% before (top 36%) (its annual reports).